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Abstract
 
Genome stability is regulated by the balance between efficiencies of the repair machinery and
genetic alterations such as mutations and chromosomal rearrangements. It has been postulated
that deregulation of class switch recombination (CSR) and somatic hypermutation (SHM),
which modify the immunoglobulin (Ig) genes in activated B cells, may be responsible for ab-
errant chromosomal translocations and mutations of non-Ig genes that lead to lymphocyte ma-
lignancy. However, the molecular basis for these genetic instabilities is not clearly understood.
Activation-induced cytidine deaminase (AID) is shown to be essential and sufficient to induce
both CSR and SHM in artificial substrates in fibroblasts as well as B cells. Here we show that
constitutive and ubiquitous expression of AID in transgenic mice caused both T cell lympho-
mas and dysgenetic lesions of epithelium of respiratory bronchioles (micro-adenomas) in all in-
dividual mice. Point mutations, but not translocations, were massively introduced in expressed
T cell receptor (
 
TCR
 
) and c
 
-myc
 
 genes in T lymphoma cells. The results indicate that AID can
mutate non-Ig genes including oncogenes, implying that aberrant AID expression could be a
cause of human malignancy.
Key words: class switch recombination • somatic hypermutation • genomic instability • 
lymphoma • T cell receptor gene
 
Introduction
 
Antigen stimulation of mature B lymphocytes induces so-
matic hypermutation (SHM)
 
*
 
 and/or class switch recombi-
nation (CSR) that diversify the variable (V) region and the
heavy-chain constant (C
 
H
 
) region genes of Ig, respectively
(1, 2). SHM introduces point mutations in rearranged V re-
gion genes, generating antibodies with higher affinity to
antigens when coupled with selection by limited amounts
of antigens (2). In parallel, the Ig heavy-chain genes also
undergo another genetic alteration, CSR, to produce anti-
bodies of various isotypes (IgG, IgA, or IgE) that carry
different effector functions with the same antigen specific-
ity. CSR changes the Ig C
 
H
 
 region gene to be expressed
from C
 
 
 
 to one of the other C
 
H
 
 genes by looping-out de-
letion of C
 
H
 
 genes by recombination between 
 
 
 
 switch
(S
 
 
 
) region and one of downstream switch (S) regions lo-
cated 5
 
 
 
 to each C
 
H
 
 gene (1).
These frequent genetic alterations in the Ig loci have
been suspected to be responsible for the genome instability.
In fact, chromosomal translocations involving Ig loci are
one of hallmarks of mature B cell lymphomas (3) and mul-
tiple proto-oncogenes are hypermutated in B cell diffuse
large-cell lymphomas (DLCLs) in a similar way to SHM of
Ig genes (4). As a large number of B cell lymphomas origi-
nate in germinal centers (GCs) where CSR and SHM take
place, these chromosomal translocations and mutations are
supposed to be mediated by aberrant hypermutation and
class switching activity in GC B cells (3). However, the
molecular basis for such deregulation of CSR and SHM ac-
tivity has not been clearly described.
Activation-induced cytidine deaminase (AID) is specifi-
cally expressed in germinal center B cells (5) and has been
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shown to be required for both SHM and CSR (6, 7). Fur-
thermore, expression of AID alone is sufficient to induce
CSR and SHM in transcribed artificial constructs in fibro-
blasts as well as B cells (8–10). Thus, we speculated that de-
regulation of AID could lead to aberrant CSR and SHM
activity and play a critical role in lymphomagenesis. In the
present study, we generated transgenic (Tg) mice that ex-
press AID constitutively and ubiquitously to test this possi-
bility. We found that AID Tg mice develop malignant T
cell lymphomas and micro-adenomas in lung, and that the
T lymphoma cells had frequent point mutations in ex-
pressed TCR and 
 
c-myc
 
 genes, which appeared to be intro-
duced by AID activity. Our results suggest that ectopic or
deregulated expression of AID might be responsible in part
to human malignancy.
 
Materials and Methods
 
Tg Mice.
 
Murine AID cDNA (0.6 kb) were cloned into the
EcoRI site of the pCXN2 vector (11) containing the chick 
 
 
 
 ac-
tin (CAG) promoter. The purified SalI-HindIII fragment con-
taining the AID transgene was microinjected into either C57BL/6
or (C57BL/6 
 
 
 
 C3H/He) F
 
2
 
 fertilized eggs to generate the B1,
2, and C1–3 lines of AID Tg mice, respectively. All Tg lines were
maintained, in specific pathogen-free condition in the animal fa-
cility of the Department of Medical Chemistry, as hemizygotes
by backcrossing male Tg mice with wild-type C57BL/6 females.
Control mice were littermates carrying no transgene. Expression
of AID in Tg tissues was analyzed by RT-PCR using following
primers: AID-S1 (5
 
 
 
-CGGCATGAGACCTACCTCTGCTAC-
3
 
 
 
) and AID-R1 (5
 
 
 
-CCAGGCTTTGAAAGTTCTTTCACG-
3
 
 
 
). AID transcripts were amplified 30 cycles for Wt and 20 cycles
for Tg mice. As an internal control, GAPDH transcripts were
amplified by 20 cycles of PCR as described (12).
 
Histology.
 
Tissues were fixed with 10% formalin in PBS and
embedded in paraffin. Sections were stained with hematoxylin
and eosin by standard method. For immunofluorescence studies,
tissue samples were frozen in tissue-tek O.C.T. compound
(Sakura Finetechnical). Sections (8 
 
 
 
m thick) were prepared and
fixed in CytoFix/CytoPerm reagent (BD Biosciences) for 10
min. Biotinylated anti-IgM (Cappel), FITC-conjugated anti-
CD4 (clone RM4–5; eBioscience), streptavidin-Texas Red
(Vector) were used for staining. The sections were mounted in
Slow Fade (Molecular Probes), and slides were analyzed with a
Bio-Rad confocal laser scanning microscope (Model MCR-
1024).
 
Flow Cytometry.
 
Single suspensions from spleens, thymi, and
lymph nodes were stained with following antibodies: FITC- or
PE-conjugated anti-CD3 (clone 145–2C11), APC-conjugated
anti-B220 (clone RA3–6B2), PE-conjugated anti-CD4 (clone
RM4–5), APC-conjugated anti-CD8 (clone 53–6.7), FITC-
conjugated anti-TCR
 
 
 
 (clone H57–597), PE-conjugated anti-
PD-1 (clone J43), streptavidin-APC (eBioscience), and biotin-
ylated-anti V
 
 
 
8 (clone F23.1; BD Biosciences). At least 10,000
live cells were analyzed on a FACSCalibur™ and CELLQuest™
software (Becton Dickinson). Dead cells were excluded from the
analysis by forward and side scatter intensity and propidium io-
dide gating.
 
Southern Blot Analysis.
 
Genomic DNA was isolated by stan-
dard procedure. 2 
 
 
 
g of genomic DNA was digested with EcoRI
and electrophoresed on a 0.7% agarose gel. Southern blots were
 
hybridized with a 
 
32
 
P-labeled 2.3 kb TCR J
 
 
 
2 probe containing
J
 
 
 
2.1–2.6 segments (13).
 
Spectral Karyotyping.
 
Lymphoma cells derived from primary
mice or SCID mice were grown in RPMI 1640 supplemented
with 10% heat-inactivated fetal calf serum, 2 mM 
 
l
 
-glutamine,
86.4 
 
 
 
M 2-mercaptoethanol, and antibiotics. Cells were ar-
rested at mitosis by treatment with colcemid (KaryoMAX Col-
cemid solution; GIBCO BRL) at 200 ng/ml for 2–3 h. Mitotic
chromosome spreads were prepared by standard procedures,
and spectral karyotyping
 
 (
 
SKY) analysis was performed as de-
scribed (14). A SkyPaint probe mixture (Applied Spectral Imag-
ing), which contains all 21 combinatorially labeled painting
probes specific for each mouse chromosome, was used for hy-
bridization.
 
Sequencing.
 
Rearranged TCR V
 
 
 
8 genes and the c
 
-myc
 
 gene
were amplified by genomic PCR using following primers:
V
 
 
 
8F1 (5
 
 
 
-CATGGAGGCTGCAGTCACCCAAAG-3
 
 
 
) and
J
 
 
 
2.7R1 (5
 
 
 
-GGACCGAAGTACTGTTCATAGGAGC-3
 
 
 
) for
TCR V
 
 
 
8, and myc575F (5
 
 
 
-GCGTTTTTTTCTGACTCG-
CTGTAG-3
 
 
 
) and myc1556R (5
 
 
 
-GCGGGGGTCAGGCT-
AAATTTTACT-3
 
 
 
) for c-myc. Genomic PCR was performed
35 cycles using Pyrobest polymerase (TaKaRa). The PCR prod-
ucts were A-tailed using rTaq polymerase (TaKaRa), subcloned
into pGEM-Teasy vector (Promega), and sequenced. V
 
 
 
8-C
 
 
 
2
transcripts from rearranged alleles were amplified by RT-PCR
using the following primers: V
 
 
 
8F1 and C
 
 
 
2R2 (5
 
 
 
-AGGGT-
GAAGAACGGCTCAGGATGC-3
 
 
 
). RT-PCR was performed
35 cycles and the products were sequenced, as described for ge-
nomic PCR.
 
Results
 
AID Transgenic Mice Die Rapidly with Enlarged Lymphoid
Organs.
 
To elucidate whether deregulated expression of
AID is involved in genetic instability, we generated five
independent lines of Tg mice expressing AID under the
control of CAG promoter (11). Although in normal mice,
AID is expressed specifically in activated B lymphocytes
(5), previous in vitro studies showed that AID could func-
tion not only in activated B cells but also in T cells and fi-
broblasts (8–10). Expression of AID in Tg tissues was con-
firmed by RT-PCR using young and healthy mice (Fig. 1
a). In Tg mice, AID was expressed ubiquitously and the
expression level was not dramatically different among tis-
sues including T and B cells in spleen. In wild-type mice,
endogenous AID was expressed at low levels in mesen-
teric lymph nodes and spleen consistent with our previous
result (5). AID Tg mice were born healthy except that
they tended to be slightly smaller than their wild-type lit-
termates (unpublished data). Flow cytometric analysis us-
ing surface markers showed that the total numbers and
compositions of B and T lymphocytes including pre-B,
pro-B, and mature B cells in spleen, lymph nodes, thy-
mus, and bone marrow of young Tg mice were indistin-
guishable from those of their wild-type littermates (un-
published data), suggesting that premature, continuous
expression of AID does not disrupt the general develop-
ment of B and T cells.
However, all Tg lines had greatly shorter life spans than
wild-type littermates (Fig. 1 b). Mice of all Tg lines diedT
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with enlarged lymphoid organs but with variations in
terms of onset of swelling and life spans. A line designated
as B1 was chosen for more detailed analyses because it de-
veloped the phenotype at youngest ages. While lymphoid
organs of the B1 Tg mice were enlarged with age, there
were two groups that were distinguished by enlargement
or shrinkage of thymus. In 65% of AID Tg mice, spleen
and systemic lymph nodes were enlarged, whereas thymi
were reduced in size to almost unrecognizable levels (Fig.
1 c). In contrasts, thymi of the remaining 35% of Tg mice
were extremely enlarged with frequent enlargements of
peripheral lymphoid organs (unpublished data). Histolog-
ical analysis of enlarged lymphoid organs revealed that
spleen, lymph nodes and thymus were filled with monot-
onous atypical lymphocytes with cytological features of
 
lymphoblastic lymphoma such as enlarged round nuclei,
irregular nuclear contours, scant cytoplasm, and frequent
mitotic figures (Fig. 2, a–c). In affected lymph nodes,
normal B cell follicles and T cell zones were destroyed
and occupied by larger T cells weakly expressing CD4
(Fig. 2 b). Furthermore, lymphoma cells invaded mas-
sively in nonlymphoid organs including liver, kidney,
lung (Fig. 2 c), pancreas, and occasionally heart (unpub-
lished data).
 
AID Transgenic Mice Develop Malignant T Cell Lymphomas
and Micro-adenomas/Adenocarcinomas in Lung.
 
Strikingly,
flow cytometric analyses revealed that lymphoma cells in
all AID Tg mice were from T cells but not B cells. This is
also the case in other Tg lines than the B1 line. Lym-
phoma cells in mice that had enlarged spleen and lymph
nodes, and minute thymus were abnormally large, CD4
 
dull
 
single positive T cells expressing CD3 and TCR
 
 
 
 (Fig. 3
a), whereas CD8
 
 
 
 single positive T cell lymphomas were
never observed in AID Tg mice. In most cases, the ex-
pression level of CD4 tended to be low and broad, and
both CD3 and TCR levels were often decreased. In addi-
tion, all lymphoma cells expressed activation markers such
as B220 (Fig. 3 a) and PD-1 (Fig. 3 c), and occasionally
CD69 (unpublished data), implying that they derived
from activated T cells in the periphery. Lymphoma cells
in mice with enlarged thymus, on the other hand, were
CD4CD8 double positive T cells expressing CD3 and
TCR
 
 
 
, suggesting that they derived from thymocytes
(Fig. 3 b). In contrast to the peripheral type, they did not
express B220 (Fig. 3 b), PD-1 (Fig.3 d), or CD69 (unpub-
lished data).
To verify the malignancy of these abnormal T cells, 2 
 
 
 
10
 
6
 
 cells from affected lymph nodes, spleens, or thymi of
six primary animals were injected either intraperitoneally
or intravenously into SCID mice or syngenic C57BL/6
mice. All of them, irrespective of strain of recipients and
the route of injection, generated lymphomas in the recipi-
ents and the mice became moribund within 3 to 6 wk af-
ter injection with enlarged lymph nodes, spleens, and
thymi. In addition, the lymphoma cells could be passed
through mice more than three times. Although the pri-
mary spleen, thymus, and lymph nodes contained normal
T and B cells in addition to the abnormal T cells, only the
abnormal T cells expanded in the recipient SCID mice
(Fig. 3, a and b and unpublished data). Furthermore, V
 
 
 
staining (Fig. 3, c and d) and Southern blot analysis of
TCR gene rearrangements (Fig. 3 e) revealed that the
lymphomas were monoclonal with both alleles rearranged
in many cases. Of 9 cases examined, 5 were monoclonally
V
 
 
 
8
 
 
 
, although the reason why V
 
 
 
8 was preferred re-
mained unclear. The transplantability and monoclonality
of the abnormal T cells indicate that they are indeed ma-
lignant T cell lymphomas.
Interestingly, all AID Tg mice from all independent
lines, even young lymphoma-free mice, developed mi-
cro-adenomas or dysgenetic lesions of respiratory bron-
chiole (Fig. 4). The number of such lesions was 
 
 
 
80 per
section of one lobe from lymphoma-developed mice and
Figure 1. Early death and enlargements of lymphoid organs in AID Tg
mice. (a) RT-PCR analysis of AID expression in wild-type and Tg tis-
sues. Young (12 wk old) and healthy mice were used for analysis.
GAPDH is an internal control. L, lung; H, heart; K, kidney; St, stomach;
I, small intestine; C, colon; Br, brain; Th, thymus; Ln, mesenteric lymph
nodes; Bm, bone marrow; Sp, spleen; B, purified splenic B cells; T, puri-
fied splenic T cells. No amplification was observed in RT( ) samples. (b)
Survival curves of five independent lines of AID Tg mice and wild-type
control. C1–3, Tg lines on C57BL/6   (C57BL/6   C3H/He) back-
ground; B1 and 2, Tg lines on C57BL/6 background. (c) Thymus (Thy),
inguinal (iLN), and mesenteric (mLN) lymph nodes and spleen (Spl) from
a 16-wk-old AID Tg mouse and its littermate control.T
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less than 30 from young (10–13 wk) and lymphoma-free
mice. These micro-adenomas were preferentially located
in subpleura areas of lung. Such distribution pattern is
quite similar to that of lung adenocarcinomas in human.
Furthermore, two out of two mice that survived more
than 60 wk had adenocarcinoma of bronchilo-alveolar
type in addition to T lymphoma. As the number and size
of micro-adenomas appeared to be larger in older mice
(unpublished data), this benign micro-adenoma might
have progressed to malignant adenocarcinoma when
mice lived long by surviving from T lymphoma. Nota-
bly, 2 out of 25 mice that survived more than 30 wk had
benign epidermalcystes in addition to T lymphoma and
 
micro-adenomas in lung, while epithelium of gastrointes-
tinal tracts of those Tg mice appeared normal (unpub-
lished data). Thus, AID could potentially affect many tis-
sues, although the susceptibility seemed different among
tissues.
 
Point Mutations but Not Translocations Are Introduced in
Expressed TCR and c-myc Genes in T Lymphoma Cells.
 
SKY
of five lymphomas revealed that lymphomas had no ap-
parent chromosomal translocations (Fig. 5 a) although
gains and losses of random chromosomes were occasion-
ally observed in some metaphases, indicating that the
lymphomas did not arise from a specific chromosomal
translocation. The fact that AID introduces hypermuta-
Figure 2. Histological analysis of lymphomas in AID Tg mice. (a) Hematoxylin and eosin staining of spleen and thymus from AID Tg and wild-type
mice. Scale bar: 250  m. (b) Immunohistochemical staining of lymph nodes from an AID Tg mouse and a wild-type control. Green, CD4; red, IgM. (c)
Lymphoma infiltration into liver, kidney, and lung in AID Tg mice. Enlarged round nuclei, irregular nuclear contours, scant cytoplasm, and frequent mi-
totic figures of lymphoma cells are evident. Scale bars: 250  m for top panels and 50  m for bottom panels.T
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tions in the 
 
GFP
 
 gene, Ig genes, and the AID transgene
per se in AID-overexpressing cells in vitro (8–10, 15) led
us to examine whether AID mutated non-Ig genes in the
lymphomas. We first sequenced the rearranged and ex-
pressed 
 
TCR
 
 genes of three lymphomas (lymphomas 1, 2,
and 4) of monoclonal V
 
 
 
8
 
 
 
 T cells. Sequenced were
products of genomic PCR using primers located in V
 
 
 
8
and J
 
 
 
2.7 segments. The rearrangements were all pro-
ductive and comprised of either V
 
 
 
8.2-J
 
 
 
2.4 (lympho-
mas 1 and 2) or V
 
 
 
8.2-J
 
 
 
2.5 (lymphoma 4). The junc-
tions of recombination were identical among all the
plasmid clones from each lymphoma, confirming its
clonality (unpublished data). This result was in marked
contrast to wild-type lymph node T cells, which con-
tained heterogeneous junctions and nonproductive rear-
rangements.
Massive numbers of point mutations were found in the
V
 
 
 
 sequences, while sequences from wild type T cells
 
had almost no mutations (Fig. 5 b and Table I). There
were mutations common among all plasmid clones from
the same lymphoma in addition to sporadic mutations,
suggesting that a single T cell with some mutations ex-
panded as lymphoma and that additional mutations con-
tinuously accumulated during subsequent proliferation.
Interestingly, mutations were also found in the C
 
 
 
2 re-
gion, which was amplified by RT-PCR between V
 
 
 
8
and 3
 
 
 
 end of C
 
 
 
2. However, mutations in the C
 
 
 
2 re-
gion were much less than those in the V
 
 
 
8 region and lo-
cated only in exon 1 and never in exon 2–4 (Table I).
Considering that exon 1 is 3 kb downstream of the J
 
 
 
2.7
segment and exon2 is further 0.5 kb downstream, the dis-
tance from the promoter might explain less mutations in
the C region as previously described in SHM of both Ig
and non Ig loci (2, 4, 16). Although no mutations were
found in the 5  and 3  regions of the Fas gene (unpub-
lished data), the c-myc gene also accumulated high levels
Figure 3. Analysis of malig-
nant T lymphoma cells in AID
Tg mice. (a) Flow cytometric
analysis of lymphomas of periph-
eral origin. Splenocytes from
wild-type control (left panels)
and an AID Tg mouse (middle
panels), and lymph node cells
from a SCID mouse that re-
ceived splenocytes from the same
individual Tg mouse (right pan-
els) are compared. Data are rep-
resentative of nine affected AID
Tg mice. (b) Flow cytometric
analysis of lymphomas of thymic
origin. Thymocytes from a wild-
type control (left panels) and an
AID Tg mouse (middle panels),
and lymph node cells from a
SCID mouse that received thy-
mocytes from the same individ-
ual Tg mouse (right panels) are
compared. Data are representa-
tive of five affected AID Tg
mice. (c and d) Flow cytometric
analysis of lymphoma cells of pe-
ripheral origin (c) and thymic or-
igin (d) showing PD-1/CD3 and
V 8 profiles. Lymph node cells
(c) and thymocytes (d) from
wild-type littermates were used
as control. Broken lines, wild-
type controls; solid lines, lym-
phoma cells. (e) Southern blot
analysis of lymphoma DNA.
EcoRI-digested DNA from five
independent lymphomas was
probed with J 2 probe. DNA
from wild-type lymph node cells
and thymocytes was used as con-
trol. Arrow indicates germline
band. Lymphomas 1–3 and 5 are
of peripheral origin, and 4 is of
thymic origin. Lymphomas 1
and 4 are shown in (a and c) and
(b and d), respectively.T
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of mutations in the region encompassing the exon 1 and
intron 1, the hotspot of mutations and breakpoints of
translocations in B cell DLCLs (4) and Burkitt lympho-
mas (3, 17–19; Fig. 5 c, Table I). Point mutations in this
region of the c-myc gene are known to alter myc transcrip-
tion by releasing a blockade mechanism on transcriptional
elongation (17, 19). Furthermore, targeted bases were
strongly biased to GC bases and base substitution pattern
was almost all either C to T or G to A (Fig. 5 d), consis-
tent with the feature of mutations found in AID-overex-
pressing cells (9, 10) and in DLCLs (4). Therefore, we
concluded that the mutations in the T lymphomas are at-
tributable to AID activity.
Life Spans of AID Transgenic Mice Are Shortened with the
Passage of Generations. Unexpectedly, one of Tg lines,
B2, which had much slower manifestation of T lym-
phoma in the parental mouse, showed an earlier onset of
T lymphomas and a clear reduction of life spans with the
passage of generations (Fig. 6), suggesting that some ef-
fects, probably mutations, caused by AID expression may
be accumulated in germ cells. The reduction of life spans
appears to stop after it reached the level of the B1 line,
progenies of which did not show any reduction of life
spans (unpublished data).
Discussion
We have shown that mice constitutively expressing AID
succumbed to T cell lymphomas. Furthermore, the mice
developed micro-adenomas and adenocarcinomas in lung.
Strikingly, point mutations but not translocations were
massively introduced in the rearranged and expressed TCR
genes as well as in the c-myc proto-oncogene with similar
distribution and base specificity to those observed in B cells
(2), B lymphomas (4), and AID-overexpressing cells in
vitro (9, 10, 15). Although a recent study showed that mul-
tiple proto-oncogenes are hypermutated in DLCLs (4)
which are derived from GC B cells and express AID,
whether these SHM-like mutations and expression of AID
are responsible to or resultant from lymphomagenesis is un-
clear since most tumor cells are genetically unstable (20).
However, our findings indicate that deregulated or ectopic
expression of AID contributes to tumorigenesis by intro-
ducing mutations in non-Ig genes rather than generating
chromosomal translocations. This is the first report of tu-
morigenesis by a gene product that can act as a direct, po-
tent mutator, but not by breakdown of systems that ensure
the genome stability.
The marked reduction of life spans in progenies of the
B2 line, which originally showed slower onset of diseases,
implies that mutations affecting tumor susceptibility accu-
mulated in germ cells. Since generation transfer of Tg mice
were mediated by three males and all Tg progenies of the
same generation showed similar phenotypes, the number
of mutation targets that are probably involved in tumor
susceptibility or life spans may be very large. The accumu-
lation of mutations in oncogenes or tumor-suppressor
genes are thought to result in tumorigenesis (20). The ge-
nome instability is observed at both nucleotide and chro-
mosomal levels. Defects in the repair systems such as nu-
Figure 4. Development of micro-adenoma and adenocarcinoma in lung of AID Tg mice. Hematoxylin and eosin staining of lung from wild-type con-
trol and AID Tg mice. Arrows indicate micro-adenomas of respiratory bronchiole. Old AID Tg mice (84- and 67-wk-old) developed adenocarcinomas
of bronchilo-alveolar type. Scale bars: 250  m for top panels and 50  m for bottom panels.T
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cleotide-excision repair and mismatch repair (MMR)
systems are involved in subtle sequence instabilities, while
defects in the checkpoint machinery such as mitotic spin-
dle checkpoint and DNA-damage checkpoint systems are
involved in chromosomal instabilities including gains and
losses of whole chromosomes and chromosomal transloca-
tions (20). Curiously, mice lacking genes involved in ei-
ther the MMR system (Msh2 [21, 22]) or the checkpoint
Figure 5. Frequent point mutations in the rearranged
TCR and the c-myc genes in lymphoma cells. (a) SKY
analysis of lymphoma cells from AID Tg mice. Data is rep-
resentative of lymphomas from five mice. Shown are the
inverted image of a 4 , 6-diamidino-2-phenylindole dihy-
drochloride (DAPI)-stained metaphase spread (G-band-
like image) (left); spectral color image of the same
metaphase spread (middle); karyotype of the spectra-based
classification-colored chromosomes and their correspond-
ing inverted DAPI images (right). (b) Distribution of mu-
tations in the rearranged TCR  genes of lymphomas from
three independent Tg mice. Data of lymphomas 1, 2, and
4 are shown. p, primary cells; s, cells recovered from SCID
mice. Red dots indicate mutations common to all plasmid
clones from the same individual mice; black dots, sporadic
mutations. Primers used for amplification are shown above
genomic loci. (c) Mutations in the c-myc gene of lym-
phoma 1 from SCID mice. Primers used for amplification
are shown above genomic locus. (d) Mutation patterns of the TCR  and c-myc genes. Frequency of mutated bases is corrected for the base composition
of the unmutated sequences. The number of mutations is shown in parentheses.T
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machinery (p53 [23], Atm [24], Brca1 [25], and Brca2 [26])
develop T cell lymphomas almost exclusively or preferen-
tially. Such exclusive occurrence of T cell lymphomas was
also observed in AID Tg mice. The reason why other
types of tumors than T lymphomas were rarely observed in
AID Tg mice may be simply because T lymphoma cells
take off and expand well in advance of generation of tu-
mors in other cells. Although the reason why no B cell
lymphoma developed is also unclear, it is possible that B
cells have a protective system to prevent excessive activity
of AID, making the onset of B lymphomagenesis slower
than that of T lymphomagenesis. However, many types of
tumors might potentially occur because in AID Tg mice
mutations were introduced in the c-myc and probably
other proto-oncogenes.
AID shows homology to apolipoprotein B mRNA ed-
iting catalytic subunit 1, APOBEC-1, a member of
RNA-editing cytidine deaminase family (5, 27). Tumori-
genesis in AID Tg mice is reminiscent of development of
hepatocellular carcinomas in mice ectopically expressing
APOBEC-1 in liver (28). Other hepatic mRNAs in-
volved in cell growth and regulation than apo-B mRNA
were aberrantly edited in APOBEC-1 Tg mice (28, 29).
As the apo-B gene in Tg livers was not mutated (28), the
mechanism for tumorigenesis in APOBEC-1 Tg mice
may be attributed to aberrant editing of mRNAs, but not
to direct action on DNA. On the contrary, non-Ig genes
including the c-myc proto-oncogene were mutated in
AID Tg mice in a similar way to the Ig gene, although
whether AID acts on RNA or DNA is still controversial
(1, 5, 30–32).
As constitutive expression of AID causes tumorigene-
sis, expression of AID has to be tightly regulated in nor-
mal mice. Otherwise, deregulatedly or ectopically ex-
pressed AID will cause enormous genomic instability.
Thus, ectopic expression of AID could be partly responsi-
ble to malignancy in mouse as well as human. It is impor-
tant to screen whether AID is ectopically expressed in
human cancers of non-B cell origins. In addition, AID Tg
mice might be a better model system to screen tumor-
suppressor genes, as mutations in AID Tg mice are re-
stricted to transcribed genes and accumulate through gen-
erations.
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Table I. Mutations in the Rearranged TCR and the c-myc Genes 
in Lymphomas
Cell source
Number of
mutated
clones
10 4   mutation
frequencya
TCRV 8–J 2 (genome)
Lymphoma 1 Primary LN 23/23 25 (41/16,330)
Transferred 24/24 15 (25/17,040)
Lymphoma 2 Primary SPL 24/24 19 (32/17,136)
Transferred 24/24 11 (19/17,136)
Lymphoma 4 Primary THY 24/24 5.4 (8/14,832)
Transferred 23/23 2.1 (3/14,214)
Wild-type LN 1/22 0.68 (1/14,799)
TCR V 8–C 2 (cDNA)
Lymphoma 1 Transferred
V 8–J 2.4 29/29 12 (11/9,019)
C 2 Exon 1–4 29/29 3.9 (6/15,486)
Exon 1 29/29 5.5 (6/10,875)
Exon 2–4 0/29  2.2 (0/4,611)
Wild-type T cells
V 8–J 2 0/24  1.3 (0/7,411)
C 2 Exon 1–4 0/24  0.78 (0/12,816)
c-myc (genome)
Lymphoma 1 Transferred 19/19 13 (24/18,183)
Wild-type LN 0/21  0.50 (0/20,097)
Identical mutations in different plasmid clones from the same individual
lymphomas were counted only once unless genealogies indicated that
the mutation was unique.
aNumber of mutations per number of total base pairs sequenced is
shown in parentheses.
Figure 6. Reduction of life spans of AID Tg mice with the passage of
generations. Separate survival curves of the founder (P) and F1, F2, and F3
Tg progenies of line B2 mice.T
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